Position in ACLX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$662,972,517
+$289,766,674 QoQ
Shares Held
5,774,016
+0.9% QoQ
Ownership
9.87%
of shares outstanding
% of Portfolio
13.55%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2022
14 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ACLX Over Time
Shares Held
Position Value (USD)
Derivatives in ACLX
reported options exposure · as of Sep 30, 2024CallValue
$66,808,000
CallShares
800,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026Paradigm Biocapital Advisors LP holds $4,894,261,596 across 35 Biotechnology names. ACLX ranks #1 (13.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ACLX |
Arcellx, Inc.
This page
|
5,774,016 | $662,972,517 | |
| 2 | RVMD |
Revolution Medicines, Inc.
|
6,655,703 | $647,267,116 | |
| 3 | NUVL |
Nuvalent, Inc.
|
5,324,433 | $545,488,160 | |
| 4 | PCVX |
Vaxcyte, Inc.
|
4,793,020 | $278,522,392 | |
| 5 | EWTX |
Edgewise Therapeutics, Inc.
|
7,365,038 | $231,998,697 | |
| 6 | GMAB |
Genmab A/S
|
7,967,836 | $213,777,039 | |
| 7 | INSM |
INSMED Inc
|
1,254,488 | $205,133,877 | |
| 8 | TARS |
Tarsus Pharmaceuticals, Inc.
|
2,562,154 | $179,735,103 |
All Filings in ACLX
Export CSV
15 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $662,972,517 | 5,774,016 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $373,205,843 | 5,724,016 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $381,684,213 | 4,649,016 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $306,137,703 | 4,649,016 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $294,677,299 | 4,492,032 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $335,258,080 | 4,371,601 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $334,040,000 | 4,000,000 | Shares | Sole | 2024-11-14 | |
| 2024-09-30 | $66,808,000 | 800,000 | Call | Sole | 2024-11-14 | |
| 2024-06-30 | $212,376,363 | 3,848,095 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $265,548,507 | 3,818,095 | Shares | Sole | 2024-05-15 | |
| 2023-12-31 | $203,053,632 | 3,658,624 | Shares | Sole | 2024-02-14 | |
| 2023-09-30 | $105,958,017 | 2,953,122 | Shares | Sole | 2023-11-14 | |
| 2023-06-30 | $74,212,140 | 2,347,000 | Shares | Sole | 2023-08-14 | |
| 2023-03-31 | $54,157,170 | 1,757,779 | Shares | Sole | 2023-05-15 | |
| 2022-12-31 | $27,327,488 | 882,101 | Shares | Sole | 2023-02-14 | |
| No filing history on record for this holder in this stock. | ||||||